These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 5014777)

  • 1. Antigenicity of L1210 leukemic sublines induced by drugs.
    Nicolin A; Vadlamudi S; Goldin A
    Cancer Res; 1972 Apr; 32(4):653-7. PubMed ID: 5014777
    [No Abstract]   [Full Text] [Related]  

  • 2. Differences in the immunogenicity of leukemia L1210 sublines in DBA-2 mice.
    Mihich E; Kitano M
    Cancer Res; 1971 Dec; 31(12):1999-2003. PubMed ID: 5120297
    [No Abstract]   [Full Text] [Related]  

  • 3. Selection for high immunogenicity in drug-resistant sublines of murine lymphomas demonstrated by plaque assay.
    Fuji H; Mihich E
    Cancer Res; 1975 Apr; 35(4):946-52. PubMed ID: 1090366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigenic differences between leukemia L1210 and a subline resistant to methylglyoxal-bis(guanylhydrazone).
    Kitano M; Mihich E; Pressman D
    Cancer Res; 1972 Feb; 32(2):181-6. PubMed ID: 5061638
    [No Abstract]   [Full Text] [Related]  

  • 5. Chemotherapy and immunotherapy of L1210 leukemic mice with antigenic tumor sublines.
    Nicolin A; Canti G; Marelli O; Veronese F; Goldin A
    Cancer Res; 1981 Apr; 41(4):1358-62. PubMed ID: 7011535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential expression of murine leukemia antigen on L1210 parental and drug-resistant sublines.
    Strzadala L; Opolski A; Radzikowski C; Mihich E
    Cancer Res; 1981 Dec; 41(12 Pt 1):4934-7. PubMed ID: 7306993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of tests of chemotherapeutic agents involving repeated drug treatment.
    Ullman NS; Jacquez JA
    Biometrics; 1973 Dec; 29(4):677-93. PubMed ID: 4785233
    [No Abstract]   [Full Text] [Related]  

  • 8. Serological analysis of H-2 antigens expression on the cell surface of drug- and lectin-resistant mouse tumor cells.
    Opolski A; Duś D; Radzikowski C
    Arch Immunol Ther Exp (Warsz); 1986; 34(1):21-34. PubMed ID: 3778114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Collateral sensitivity of resistant lines of mouse leukemias L1210 and L5178Y.
    Schmid FA; Hutchison DJ
    Cancer Res; 1972 Apr; 32(4):808-12. PubMed ID: 5014791
    [No Abstract]   [Full Text] [Related]  

  • 10. Differential tumor immunogenicity of DBA/2 mouse lymphoma L1210 and its sublines. III. Control of host resistance to drug-resistant L1210 sublines by H-2-linked and non-H-2-linked genes.
    Fuji H; Murakami M
    J Natl Cancer Inst; 1983 Jan; 70(1):119-25. PubMed ID: 6296515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigenic changes of L1210 leukemia in mice treated with 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide.
    Bonmassar E; Bonmassar A; Vadlamudi S; Goldin A
    Cancer Res; 1972 Jul; 32(7):1446-50. PubMed ID: 4402275
    [No Abstract]   [Full Text] [Related]  

  • 12. Potentiation of concanavalin A-bound L1210 vaccine in vivo by chemotherapeutic agents.
    Kataoka T; Kobayashi H; Sakurai Y
    Cancer Res; 1978 May; 38(5):1202-7. PubMed ID: 639053
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunologic cross-reactivity of antigen(s) induced by drug treatment in two leukemic sublines.
    Nicolin A; Bini A; Di Padova F; Goldin A
    J Immunol; 1976 May; 116(5):1347-9. PubMed ID: 58028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cytogenetic characteristics of the leukemia L1210 strain in the development of drug resistance].
    Goncharova SA; Minenkova EA; Fomina MM; Demidova NS
    Eksp Onkol; 1984; 6(4):38-41. PubMed ID: 6499750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basis of observed resistance of L1210 leukemia in mice: methotrexate, 6-thioguanine, 6-methylmercaptopurine riboside, 6-mercaptopurine, 5-fluorouracil, and 1-beta-D-arabinofuranosylcytosine administered in different combinations.
    Kim K; Blechman WJ; Riddle VG; Pardee AB
    Cancer Res; 1981 Nov; 41(11 Pt 1):4529-34. PubMed ID: 7198006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibody-recognizing tumor-associated antigen of DBA/2 mouse lymphoma L1210 and its sublines.
    Fuji H
    Transplant Proc; 1980 Sep; 12(3):388-90. PubMed ID: 6784299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential antigenic expression of the DBA/2 lymphoma L1210 and its sublines: cross-reactivity with C3H mammary tumors as defined by syngeneic monoclonal antibodies.
    Rapp L; Fuji H
    Cancer Res; 1983 Jun; 43(6):2592-9. PubMed ID: 6342755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro generation of a highly immunogenic subline of L1210 leukemia following exposure to 5-(3,3'-dimethyl-1-triazeno)imidazole-4-carboxamide.
    Contessa AR; Bonmassar A; Giampietri A; Circolo A; Goldin A; Fioretti MC
    Cancer Res; 1981 Jun; 41(6):2476-82. PubMed ID: 7016315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential tumor immunogenicity of DBA/2 mouse lymphoma L1210 and its sublines. II. Increased expression of tumor-associated antigens on subline cells recognized by serologic and transplantation methods.
    Fuji H; Mihich E; Pressman D
    J Natl Cancer Inst; 1979 Jun; 62(6):1503-10. PubMed ID: 286122
    [No Abstract]   [Full Text] [Related]  

  • 20. Drug resistance induction and cross-resistance studies with Pt-complexes.
    Hrubisko M; Balázová E; Ujházy V
    Neoplasma; 1984; 31(6):649-53. PubMed ID: 6542968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.